Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics

Lin, Chia-Yen; Wang, Shian‐Shiang; Yang, Chih-Hui; Li, Jian-Ri; Chen, Chuan-Shu; Hung, Sheng-Chun; Chiu, Kun‐Yuan; Cheng, Chen-Li; Ou, Yen‐Chuan; Yang, Shun‐Fa

doi:10.7150/ijms.38080

Cited by 25 publications

(32 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two GAS5 genetic variants rs145204276 and rs55829688 were detected in compliance with the data of International HapMap Project and previous study [28]. The polymorphism rs145204276 AGGCA/-was demonstrated to be located at the promoter region of lncRNA GAS5 and was associated with the progression of several cancers [28,29]. GAS5 genetic polymorphisms rs145204276 and rs55829688 were examined by ABI StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) as well as delineated with SDS vers.…”

Section: Selection Of Gas5 Genetic Polymorphismsmentioning

confidence: 80%

The relationships of genetic polymorphisms of the long noncoding RNA growth arrest-specific transcript 5 with uterine cervical cancer

Weng

Lee

et al. 2020

Int. J. Med. Sci.

Self Cite

View full text Add to dashboard Cite

The purposes of the investigation were to examine the implications of long noncoding RNA growth arrest-specific transcript 5 (GAS5) in progression and clinicopathological factors of uterine cervical cancer, and patient survival in Taiwan. Genotypic distributions of two GAS5 genetic variants rs145204276 and rs55829688 were detected in 208 patients including 111 patients with invasive cancer, 97 with precancerous lesions as well as 307 control women using real-time polymerase chain reaction. It explored that patients with cervical precancerous lesion had lower rate of AGGCA deletion (Del) in both alleles (Del/Del) of GAS5 rs145204276 as compared with control women. Patients with invasive cancer did not exhibit higher rate of Del/Del. Meanwhile, there were no different genotypic distributions in rs55829688 among patients with cervical invasive cancer and those with precancerous lesions as well as control women. Moreover, cervical cancer patients with Ins (insertion, AGGCA)/Del and Del/Del (-/-) in GAS5 rs55829688 tended to have poorer hazard ratio (HR) of 5 years survival. In addition, lymph node metastasis status exerted the most significantly predictive of 5 years survival rate. Conclusively, GAS5 polymorphism rs145204276 is probably applicable to predict 5 years survival HR of cervical cancer patients. However, the mechanism elucidating the methylation status and transcription function of rs145204276 in uterine cervical cancer needs to be delineated for its unique implication in uterine cervical cancer.

show abstract

Section: Selection Of Gas5 Genetic Polymorphismsmentioning

confidence: 80%

The relationships of genetic polymorphisms of the long noncoding RNA growth arrest-specific transcript 5 with uterine cervical cancer

Weng

Lee

et al. 2020

Int. J. Med. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…CE19062A). Medical information including age at diagnosis, initial prostate specific antigen (PSA) level at diagnosis, pathologic Gleason grade group, clinical and pathological TNM staging, seminal vesicle invasion, perineural invasion, lymphovascular invasion, and D’Amico classification were acquired from each patient’s medical records [ 34 , 35 , 36 , 37 ]. In this study, the Gleason grade group and D’Amico classification were grouped according to the International Society of Urological Pathology (ISUP) consensus in 2016 [ 38 ].…”

Section: Methodsmentioning

confidence: 99%

The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

Chou

Yang

Lin

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

Prostate cancer is one of the major cancers of the genitourinary tract. High-mobility group box 1 (HMGB1) was suggested as a promising therapeutic target for prostate cancer. In this study, we aim to elucidate the associations of HMGB1 single nucleotide polymorphisms (SNPs) with prostate cancer susceptibility and clinicopathological characteristics. The HMGB1 SNPs rs1412125, rs2249825, rs1045411, and rs1360485 in 579 prostate cancer patients and 579 cancer-free controls were analyzed with real-time polymerase chain reactions (real-time PCR). All of the data were evaluated with SAS statistical software. Our results showed that the HMGB1 rs1045411 T allele genotype was significantly associated with advanced pathologic T stage (odds ratio (OR) = 1.433, 95% confidence interval (CI) = 1.021–2.012; p = 0.037) and pathologic N1 stage (OR = 2.091, 95% CI = 1.160–3.767; p = 0.012), and the rs1360485 polymorphic CT + TT genotype was associated with pathologic Gleason grade group (4 + 5) (OR = 1.583, 95% CI = 1.017–2.462; p = 0.041), pathologic T stage (3 + 4) (OR = 1.482, 95% CI = 1.061–2.070; p = 0.021), and pathologic N1 stage (OR = 2.131, 95% CI = 1.178–3.852; p = 0.011) compared with their wild-type carriers. In conclusion, our results revealed that the HMGB1 SNPs were associated with the clinical status of prostate cancer. The HMGB1 SNPs may have the potential to predict prostate cancer disease progression.

show abstract

“…[130][131][132] In terms of its mechanism of action, GAS5 may act as a sponge for miR-103, which in turn, inactivates the AKT/mTOR signaling pathway, thus inhibiting prostate cancer cell proliferation. 131 In addition, two single nucleotide polymorphisms (SNPs) located in the chromosomal segment of GAS5 (rs55829688 and rs145204276) can increase GAS5 expression, [133][134][135] and are associated with improved survival in prostate cancer. 133 Patients with prostate cancer and the GAS5 rs145204276 polymorphism are associated with a low risk of pathologic N stage and seminal vesicle invasion.…”

Section: Prostate Cancermentioning

confidence: 99%

“…133 Patients with prostate cancer and the GAS5 rs145204276 polymorphism are associated with a low risk of pathologic N stage and seminal vesicle invasion. 135 Furthermore, patients with prostate cancer aged >65 years who carry the GAS5 rs145204276 polymorphism show decreased risk of clinical T stage, pathologic N stage, and lymphovascular invasion. 135 Differential expression of GAS5 due to these SNPs likely affects the miR-21/programmed cell death 4 (PDCD4)/PTEN axis, 133 as well as the miR-1284/AKT 133 and miR-1284/high mobility group box 1 (HMGB1) 134 pathways.…”

Section: Prostate Cancermentioning

confidence: 99%

“…135 Furthermore, patients with prostate cancer aged >65 years who carry the GAS5 rs145204276 polymorphism show decreased risk of clinical T stage, pathologic N stage, and lymphovascular invasion. 135 Differential expression of GAS5 due to these SNPs likely affects the miR-21/programmed cell death 4 (PDCD4)/PTEN axis, 133 as well as the miR-1284/AKT 133 and miR-1284/high mobility group box 1 (HMGB1) 134 pathways. In addition, overexpression of miR-145 can upregulate GAS5 expression, although GAS5 overexpression (or silencing) has no effect on miR-145 levels.…”

Section: Prostate Cancermentioning

confidence: 99%

See 1 more Smart Citation

<p>Long Non-Coding Small Nucleolar RNA Host Genes (SNHGs) in Endocrine-Related Cancers</p>

Qin¹,

Sun²,

Wang³

et al. 2020

OTT

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are emerging regulators of a diverse range of biological processes through various mechanisms. Genome-wide association studies of tumor samples have identified several lncRNAs, which act as either oncogenes or tumor suppressors in various types of cancers. Small nucleolar RNAs (snoRNAs) are predominantly found in the nucleolus and function as guide RNAs for the processing of transcription. As the host genes of snoRNAs, lncRNA small nucleolar RNA host genes (SNHGs) have been shown to be abnormally expressed in multiple cancers and can participate in cell proliferation, tumor progression, metastasis, and chemoresistance. Here, we review the biological functions and emerging mechanisms of SNHGs involved in the development and progression of endocrine-related cancers including thyroid cancer, breast cancer, pancreatic cancer, ovarian cancer and prostate cancer.

show abstract

Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics

Cited by 25 publications

References 45 publications

The relationships of genetic polymorphisms of the long noncoding RNA growth arrest-specific transcript 5 with uterine cervical cancer

The relationships of genetic polymorphisms of the long noncoding RNA growth arrest-specific transcript 5 with uterine cervical cancer

The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

<p>Long Non-Coding Small Nucleolar RNA Host Genes (SNHGs) in Endocrine-Related Cancers</p>

Contact Info

Product

Resources

About